secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2022-08-30T23:59:59+00:00
Accession:  0001104659-22-095769
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio appoints Henry Hagopian III as CFO, replacing Jeff McGroarty who departs
--------------------------------------------------------------------------------

- Henry Hagopian III appointed CFO effective Aug 29, 2022; Jeff McGroarty departs to pursue other interests.
- Hagopian has 30 years of finance experience, most recently SVP Finance & Treasurer at Organogenesis (ORGO).
- Compensation includes $375,000 base salary, 35% target bonus, and 120,000 stock options at $11.55 exercise price.
- Company highlights advancement of lead drug buntanetap into Phase 3 trials for neurodegenerative diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465922095769/0001104659-22-095769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465922095769/tm2224778d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-095769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer